GO
| HSI1 | 25,978.07 | +62.87 | 236.72B |
| HSCEI1 | 8,775.62 | +42.99 | 76.71B |
| Back Zoom + Zoom - Block Traded | |
|
Ascentage Pharma-B (06855.HK) Multiple Studies Selected for 2026 ASCO
2026-04-22 08:57:29 Ascentage Pharma-B (06855.HK) announced that six clinical studies of three of its key drug candidates have been selected for presentation at the 2026 Annual Meeting of the American Society of Clinical Oncology (ASCO), including three for rapid oral presentations and three for poster presentations. The three key drug candidates are olverembatinib (trade name: Nai Li Ke), the first third-generation BCR-ABL inhibitor approved for marketing in China; lisaftoclax (trade name: Li Sheng Tuo), the first domestically developed selective Bcl-2 inhibitor approved for marketing in China; and the MDM2-p53 inhibitor alrizomadlin (APG-115). (ec/da)~ AASTOCKS Financial News Website: www.aastocks.com This article was automatically translated by AI, the Chinese version should be considered the authoritative version. AASTOCKS.com Limited does not guarantee its accuracy or completeness and accepts no liability for any damages or losses arising from the use of this translation. | |